Ion Beam ApplicationsIOBCF +2.18%82 Pretax Margin % is 5.57% as of Dec. 2025, which is 98% above its 10-year median of 2.82. GuruFocus rates IOBCF with a GF Score™ of 82/100 and a GF Value™ of $18.71 (Fairly Valued). The stock has 10 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Ion Beam Applications ranks better than 50.92% on this metric.
The historical rank and industry rank for Ion Beam Applications's Pretax Margin % or its related term are showing as below:
IOBCF'
s Pretax Margin % Range Over the Past 10 Years
Min: -9.94 Med: 2.82 Max: 10.6
Current: 3.03
IOBCF's Pretax Margin % is ranked better than 50.92% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.43
vs IOBCF: 3.03
Ion Beam Applications (OTCPK:IOBCF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Ion Beam Applications Pretax Margin % Related Terms
Ion Beam Applications Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Ion Beam Applications's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOBCF vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, Ion Beam Applications's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ion Beam Applications Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ion Beam Applications's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Ion Beam Applications's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ion Beam Applications (IOBCF) has a Pretax Margin % of 5.57% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ion Beam Applications and its competitors. This is 98% above median its historical median of 2.82. According to the industry distribution chart, Ion Beam Applications ranks #401 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 49.1%.
Is Ion Beam Applications' Pretax Margin % too high?
Ion Beam Applications' current Pretax Margin % of 5.57% is 98% above median its 10-year median of 2.82. The Medical Devices & Instruments industry median Pretax Margin % is 2.43. Ion Beam Applications' value of 5.57% is 129.2% above this industry median. Based on the distribution chart, Ion Beam Applications ranks #401 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Ion Beam Applications has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ion Beam Applications' Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ion Beam Applications ranks #401 out of 817 companies for Pretax Margin %. This puts Ion Beam Applications in the upper half of its industry. The industry median Pretax Margin % is 2.43. Ion Beam Applications' value of 5.57% is 129.2% above this benchmark. While the company's 10-year median is 2.82 vs. the industry median of 2.43, Ion Beam Applications has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.43, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ion Beam Applications's current Pretax Margin % of 5.57% is 129.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ion Beam Applications and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ion Beam Applications's current Pretax Margin % is 5.57%, which is 98% above median its own 10-year median of 2.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ion Beam Applications stock overvalued right now?
Based on GuruFocus' analysis, Ion Beam Applications (IOBCF) is currently considered Fairly Valued. The stock's GF Value™ is $18.71, compared to a current price of $18.90 — trading 1% above its estimated fair value. The current Pretax Margin % is 5.57%, which is 98% above median its 10-year median of 2.82 and 129.2% above the Medical Devices & Instruments industry median of 2.43. Ion Beam Applications' overall GF Score™ is 82/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Ion Beam Applications (IOBCF), the current Pretax Margin % is 5.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ion Beam Applications (IOBCF) Overvalued in 2026?
Based on GuruFocus' analysis, Ion Beam Applications stock appears to be overvalued.
The current stock price of $18.90 is trading 1% above its estimated GF Value™ of $18.71.
GuruFocus considers Ion Beam Applications to be Fairly Valued.
Key valuation signals for IOBCF:
Pretax Margin %: 5.57% (98% above median its 10-year median of 2.82)
GF Value™: $18.71 vs. price of $18.90 (1% above fair value)
Industry Position: 129.2% above the Medical Devices & Instruments median (#401 of 817)
No single metric tells the full story. See the IOBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in three segments: IBA Clinical, including Proton Therapy and Dosimetry; IBA Technologies; and IBA Corporate. Proton therapy and other accelerators contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, China, Germany, and India.
82GF Score
Get the complete analysis for IOBCF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOBCF has been successfully added to your 
